Björn is a very experienced toxicologist with 25 years of discovery and development experience gained in AstraZeneca. Björn has worked across multiple therapy areas and has particular experience in the Cardiovascular, Renal and Metabolism therapy areas. He has been directly involved in bringing over 30 new candidate drugs to clinical trials and 4 to marketing approval. Björn was co-chair of the EFPIA Preclinical Development Expert Working Group until 2018 and was EFPIA topic lead on the ICH Expert Working Group on nonclinical safety testing of paediatric medicines. Björn brings his judgement, wisdom and problem-solving skills to the design and delivery of nonclinical strategies.